RxDoctor Payments Data

Kevin Greuloch, MD

Ophthalmology · Saint Louis, MONPI 1285654616

Payments from drug & device makers

$3,076in general payments, 2019–2025

Across 31 payments — averaging $99.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Rxsight Inc$2K
  • Alcon$518
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$318
  • Glaukos Corporation$153
  • Sight Sciences, Inc.$142
  • Bausch & Lomb Americas Inc.$125
  • plus $142 from 2 others

What the payments were for

  • Speaking & faculty fees$281%
  • Food & beverage$1,50949%
  • Education$1,50049%
  • Gifts$391%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,076 in reported general payments places this provider in the 60th percentile of 286 ophthalmology providers in Missouri.

See all ophthalmology providers in Missouri

Medicare billing

Part B allowed, 2024
$380,132
Medicare patients
1,217
Services billed
3,247

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine61$60,876
LumiganBimatoprost90$44,513
Cyclosporine47$21,161
Latanoprost592$6,553
Travoprost49$6,550
CombiganBrimonidine Tartrate/Timolol14$5,573
Brimonidine Tartrate100$5,318
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol11$4,225
Prednisolone Acetate115$4,085
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat170$2,964
Dorzolamide-TimololDorzolamide/Timolol/Pf22$2,199
Timolol Maleate106$2,138
Fluorometholone17$1,880
Tobramycin-DexamethasoneTobramycin/Dexamethasone46$1,573
Loteprednol Etabonate13$1,442

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$318$1,44213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 286 ophthalmology providers in Missouri.

Other ophthalmology in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →